Metsera, Inc.
MTSR
Classement en actions
#2573
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Prix de l'action
$70.50
Dernière synchronisation: 2025-11-14
Capitalisation boursière
$7.33B
Changement (1 jour)
0.00%
Changement (1 an)
33.60%
Pays
US
Échange Metsera, Inc. (MTSR)
Catégorie
Healthcare
Ratio P/S pour Metsera, Inc. (MTSR)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Metsera, Inc., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Metsera, Inc. de 2026 à 2026
Ratio P/S à la fin de chaque année
| Année | Ratio P/S | Changez |
|---|---|---|
| Pas assez de données pour les dates fournies. | ||
Ratio P/S pour des entreprises similaires ou concurrentes
| Entreprise | Ratio P/S | Différence de Ratio P/S | Pays |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| 10.15 | - |
NL
|
|
| - | - |
CH
|
